+7 (499) 340 10 14

First Line Therapy

Information about antiretroviral drug Atripla (Tenofovir + Emtricitabin + Efavirenz) authorized in Russia on July 19, 2016 have been published at the website of  State Register of Medicinal Remidies.

It is a combination drug for treatment of patients with HIV infection (once daily). According to WHO experts, the combination Tenofovir + Emtricitabin + Efavirenz provides the optimal effect.

It is of note, that Atripla is the second authorized combination drug. The first was Eviplera (Emtricitabmin + Rilpivirine + Tenofovir authorized in 2013.

After marketing authorization of the new combination Tenofovir + Emtricitabin + Efavirenz will be recommended as first line therapy of HIV patients.

LABMGMU LABMGMU +7 (499) 340 10 14 info@labmgmu.ru 119435, Moscow, Malaya Pirogovskay str. 13-1, floor 4